Delphi’s Sensitivity to Endocrine Therapy (SETTM) is a gene expression interpretive algorithm that measures potential disease progression on endocrine therapy in patients with hormone receptor positive HER2 negative breast cancer. The results add significant clinical information that is independent of any other tests currently on the market.
SETER/PR Index is an endocrine-related transcriptional gene signature that serves as the core technology behind the SET2,3 and SET4 tests. SET2,3 provides prognostic information independent from adjuvant and neoadjuvant chemotherapy response on Stage II-III invasive breast cancer with nodal involvement.
SET4 is an assay that employs SETER/PR in the metastatic setting and is one of the only gene signatures that has shown prognostic efficacy in Stage IV breast cancers.
To date, several proof of concept studies have been completed, supporting analytical and clinical validation. There is a robust clinical evidence plan to expand on this data and demonstrate the clinical utility of the SET tests.
The intellectual property underlying SET is the brainchild of Dr. Fraser Symmans, Professor in the Departments of Pathology and Translational Molecular Pathology at the University of Texas MD Anderson Cancer Center. Delphi Diagnostics holds the exclusive world-wide license to commercialize this intellectual property.